Wedbush Boosts Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $53.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target upped by research analysts at Wedbush from $50.00 to $53.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 21.87% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price for the company. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average price target of $55.29.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $43.49 on Wednesday. The firm’s fifty day moving average is $42.93 and its two-hundred day moving average is $39.69. The firm has a market cap of $3.30 billion, a PE ratio of 58.77 and a beta of 0.06. Kiniksa Pharmaceuticals International has a twelve month low of $18.25 and a twelve month high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% on a year-over-year basis. During the same period last year, the firm earned ($0.12) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 42,841 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer directly owned 31,086 shares in the company, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 123,623 shares of company stock valued at $5,236,389. Insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP raised its holdings in Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after acquiring an additional 90,194 shares during the period. Vanguard Group Inc. lifted its position in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after acquiring an additional 49,802 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after acquiring an additional 233,668 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after purchasing an additional 332,846 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its position in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.